“I am very pleased to notice a great interest from patients and parents of younger patients to participate in the trial,” says Professor Johnny Ludvigsson, University of Linköping, Coordinating Investigator of DIAGNODE-2. “It is our sincere hope, that we with DIAGNODE-2 now will be able to prove the beneficial clinical effects of the GAD-vaccine as it is administered directly into the lymphatic system. Preliminary data from the DIAGNODE-1 trial points to this, where patients’ own insulin producing capacity is reasonably preserved and metabolic and immune responses point in the right direction. The treatment is designed to specifically target the underlying autoimmne disease in order to preserve the remaining insulin production.”

Diamyd Medical is investigating the possibility to open additional sites in Sweden in order to further facilitate patients’ access to the trial. As of today, a total of 16 clinics are open to recruit patients; 9 in Spain, 2 in the Czech Republic and 5 in Sweden 

About type 1 diabetes
Type 1 diabetes is an autoimmune disease where the beta cells, the cells in the pancreas that produce insulin, are broken down by the immune system. GAD65 (glutamic acid decarboxylase) is an endogenous protein that is expressed by the beta cells. In autoimmune diabetes, the immune system identifies the protein as dangerous and attacks and destroys the insulin-producing cells. GAD65 is the active ingredient in the diabetes vaccine Diamyd^® being developed with the aim to reduce the immune system's sensitivity to GAD65 and thus preserving the remaining insulin production.

About DIAGNODE-2
The placebo-controlled trial DIAGNODE-2 encompasses approximately 80 patients from Spain, the Czech Republic and Sweden, aged 12–24 years. The subjects are recently diagnosed with type 1 diabetes and given the diabetes vaccine Diamyd^® (or its placebo) directly into the lymph node at three occasions, one month apart in combination with an oral vitamin D regimen (or its placebo) during four months, starting 30 days prior to the first injection. The patients are followed for 15 months with the aim to evaluate the remaining insulin producing capacity. Coordinating Investigator is Professor Johnny Ludvigsson at Linköping University.

About Diamyd Medical
Diamyd Medical is dedicated to finding a cure for diabetes and other serious inflammatory diseases through pharmaceutical development and investments in stem cell and medical technology.

Diamyd Medical develops the diabetes vaccine Diamyd^®, for antigen-specific immunotherapy based on the exclusively licensed GAD-molecule. Diamyd^® has demonstrated good safety in studies with more than 1,000 patients as well as effect in some pre-specified subgroups. Besides the Company’s own European Phase-II trial DIAGNODE-2, where the diabetes vaccine is administered directly into the lymph node, there are four investigator initiated clinical trials ongoing with Diamyd^®. Diamyd Medical also develops Remygen™, a proprietary GMP manufactured oral GABA-based study drug. An investigator initiated placebo controlled trial with GABA and Diamyd^® in patients recently diagnosed with type 1 diabetes is ongoing at the University of Alabama at Birmingham. Exclusive licenses for GABA and positive allosteric modulators of GABA receptors for the treatment of diabetes and inflammatory diseases constitutes alongside with the diabetes vaccine Diamyd^® and Remygen™ key assets. Diamyd Medical is also one of the major shareholders in the stem cell company NextCell Pharma AB and has holdings in the medtech company Companion Medical, Inc., San Diego, USA and in the gene therapy company Periphagen, Inc., Pittsburgh, USA.

Diamyd Medical’s B-share is traded on Nasdaq First North under the ticker DMYD B. FNCA Sweden AB is the Company’s Certified Adviser.

For further information, please contact:
Ulf Hannelius, President and CEO
Phone: +46 736 35 42 41
E-mail: ulf.hannelius@diamyd.com

Diamyd Medical AB (publ)
Kungsgatan 29, SE-111 56 Stockholm, Sweden. Phone: +46 8 661 00 26, Fax: +46 8 661 63 68
E-mail: info@diamyd.com Reg. no.: 556242-3797 Website: www.diamyd.com

This information is information that Diamyd Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08:17 CET on February 9, 2018.